These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. Kim JS; McSweeney J; Lee J; Ivy D Pediatr Crit Care Med; 2016 Mar; 17(3 Suppl 1):S89-100. PubMed ID: 26945333 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. Hellawell JL; Bhattacharya S; Farber HW Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984 [TBL] [Abstract][Full Text] [Related]
49. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. Madonna R; Cocco N; De Caterina R Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170 [TBL] [Abstract][Full Text] [Related]
50. Pathways in pulmonary arterial hypertension: the future is here. Sitbon O; Morrell N Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120 [TBL] [Abstract][Full Text] [Related]
51. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Mirza S; Foley RJ Clin Med Insights Circ Respir Pulm Med; 2012; 6():41-50. PubMed ID: 22872790 [TBL] [Abstract][Full Text] [Related]
52. Pulmonary arterial hypertension: on the way to a manageable disease. Mucke HA Curr Opin Investig Drugs; 2008 Sep; 9(9):957-62. PubMed ID: 18729002 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model. Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621 [TBL] [Abstract][Full Text] [Related]
55. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466 [TBL] [Abstract][Full Text] [Related]
56. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960 [TBL] [Abstract][Full Text] [Related]
57. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension. Kuwana M; Abe K; Kinoshita H; Matsubara H; Minatsuki S; Murohara T; Sakao S; Shirai Y; Tahara N; Tsujino I; Takahashi K; Kanda S; Ogo T Pulm Circ; 2023 Jan; 13(1):e12198. PubMed ID: 36788940 [TBL] [Abstract][Full Text] [Related]
58. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198 [TBL] [Abstract][Full Text] [Related]